Immunostaining for cytoplasmic

myosin VI and membranous E-cadherin was classified as follows: negative and weak selleck compound positive were considered negative and moderate and strong positive were considered positive. Immunostaining was classified negative and positive for nuclear myosin VI, E-cadherin and beta-catein as well as cytoplasmic beta-catein. The result was considered positive when any staining was detected. Statistical analyses SPSS for Windows 15 (Chicago, IL, USA) was used for statistical analyses. The chi-squared test or Fisher’s exact test was used to study associations between different variables. Survival was analysed with the Kaplan-Meier curve and significance with the log rank test. The Cox regression multivariate model was used for multivariate analysis using Fuhrman grade, stage, tumour Selleckchem LY3009104 diameter, age or gender as adjusting factors. Results Patient demographics and staining correlation with clinical parameters At the time of diagnosis, the median age of patients was 63 years (range 29-86 years). Seventy-seven (51%) patients were women and 75 (49%) men. The median follow-up time was 90 months (range 0-209 months). During follow-up, 44 (29%) patients click here died because of RCCs, 40 (26%) died of other causes and 68 (45%) patients were still alive. The distribution of tumour classes (TNM classification), clinical stages, tumour grades and the histological subtype

of the RCC in comparison to the immunostaining pattern for myosin VI, beta-catenin and E-cadherin are described in Table 1, Table 2 and Table 3, respectively. Table 1 Associations between immunostaining for myosin VI and tumour class, stage, grade and histological subtype of RCC.   Cytoplasmic myosin VI Nuclear myosin VI   positive negative positive negative Tumour class (T)         1 (n = 71) 54 (76%) 17 (24%) 25 (35%) 46 (65%) 2 (n = 11) 6 (55%) 5 (45%) 3 (27%) 8 (73%) 3 (n

= 57) 41 (72%) 16 (28%) 20 (35%) 37 (65%) 4 (n = 6) 3 (50%) 3 (50%) 3 (50%) 3 (50%) Stage         I (n = 66) 50 (76%) 16 (24%) 23 (35%) 43 (65%) II (n = 11) 6 (55%) 5 (45%) 3 (27%) 8 (73%) Non-specific serine/threonine protein kinase III (n = 49) 35 (71%) 14 (29%) 19 (39%) 30 (61%) IV (n = 19) 13 (68%) 6 (32%) 6 (32%) 13 (68%) Grade         I (n = 5) 5 (100%) 0 (0%) 1 (20%) 4 (80%) II (n = 79) 59 (75%) 20 (25%) 31 (39%) 48 (61%) III (n = 38) 28 (74%) 10 (26%) 10 (26%) 28 (74%) IV (n = 21) 10 (48%) 11 (52%) 8 (38%) 13 (62%) Histological subtype of RCC         clear cell (n = 128) 89 (70%) 39 (30%) 46 (36%) 82 (64%) papillary (n = 10) 9 (90%) 1 (10%) 2 (20%) 8 (80%) chromophobic (n = 5) 4 (80%) 1 (20%) 2 (40%) 3 (60%) undifferentiated (n = 2) 2 (100%) 0 (0%) 1 (50%) 1 (50%) Number of patients with different characteristics and respective cytoplasmic and nuclear myosin VI immunostaining are presented. Table 2 Associations between immunostaining for beta-catenin and tumour class, stage, grade and histological subtype of RCC.